Senores Pharmaceuticals Ltd. Company History and Annual Growth Details

Our Company was originally incorporated as ÂSenores Pharmaceuticals Private LimitedÂ a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.

The name of the Company was thereafter changed to ÂSenores Pharmaceuticals LimitedÂ upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.

Major Events and Milestones:

2021

- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.

2021

- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited

2022
- Started the domestic business with a launch of the critical care injectables

2024
- Launched first CMO product in the US with Jubilant Cadista.

2025

-Senores Pharmaceuticals receives Philippine FDA approval for 10 products.

-The Company Acquired of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals.

Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article